Peer-reviewed discovery platform and data in PNAS show that single transcription factor modulation reverses aging-associated gene expression and restores healthy cellular and tissue function in models ...

Bayer AG enters into collaborations to develop a heart-targeted siRNA therapy and AI technology, expanding its push into next ...

Hong Kong investors can now trade in their first mRNA concept stock, following the strong trading debut for Suzhou Ribo Life ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, ...

In addition to its Chinese R&D and manufacturing centers in Beijing and Suzhou, Ribo also set up a subsidiary, Ribocure AB, ...

Ribo's IPO is aiming to raise around HKD 1.59 billion (around $205 million) through the sale of 27.5 million shares at HKD 57 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship manufacturing facility in Massachusetts. Alnylam plans to spend $250 million in a ...

Genetic, biochemical and structural studies have implicated Argonaute proteins as the catalytic core of the RNAi effector complex, RISC. Here we show that recombinant, human Argonaute2 can combine ...

Bayer & Soufflé Therapeutics enter strategic collaboration to advance cell-specific heart-targeted siRNA therapy: Berlin, Germany Friday, January 9, 2026, 09:00 Hrs [IST] Bayer a ...